Marksans Pharma arm wins UK nod for high blood pressure drug Moxonidine

Marksans Pharma Ltdon Tuesday announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for moxonidine tablets in 200 and 400 microgram strengths. Moxonidine is prescribed for the treatment of high blood pressure.

The approval adds to Relonchem’s growing portfolio in the UK. Earlier in June, the subsidiary secured marketing authorisation for oxybutynin hydrochloride oral solution, used for managing symptoms of overactive bladder.

Marksans has also been strengthening its US presence — on June 30, its arm Time-Cap Laboratories received an Establishment Inspection Report from the US Food and Drug Administration for its New York facility.

Financially, the company faced a weaker first quarter of FY26. Consolidated net profit fell 34.3% year-on-year to ₹58.3 crore, weighed down by ramp-up costs, a one-time expected credit loss provision, and forex adjustments.

Revenue, however, rose 5% to ₹620 crore, supported by new launches in the US and easing raw material costs. Gross profit grew nearly 9%, but EBITDA slipped 22% to ₹100 crore, with margins narrowing to 16.1% from 21.7% last year.

Managing Director Mark Saldanha acknowledged the quarter was seasonally soft but emphasised that the factors impacting profitability were transient and did not alter the company’s long-term growth trajectory.

As of 2:46 pm, shares of Marksans Pharma were trading at ₹171.72 on the NSE, down 1.45%.